RecruitingNot ApplicableNCT06361316
Irinotecan Liposome Combined With Oxaliplatin and Tegafur as Adjuvant Therapy for Pancreatic Cancer
Efficacy and Safety of Irinotecan Liposome Injection Combined With Oxaliplatin and Tegafur (NASOX) in Adjuvant Chemotherapy for Pancreatic Cancer
Sponsor
Kuirong Jiang
Enrollment
53 participants
Start Date
Apr 8, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to evaluate the efficacy and safety of irinotecan liposome injection in combined with oxaliplatin plus tegafur (NASOX) for postoperative adjuvant chemotherapy for pancreatic cancer.
Eligibility
Min Age: 18 YearsMax Age: 75 Years
Inclusion Criteria5
- ECOG performance status 0 or 1.
- Histologically confirmed resected ductal pancreatic adenocarcinoma with macroscopic complete resection (R0 and R1).
- ECOG performance status 0 or 1.
- Life expectancy of greater than or equal to 6 months.
- Able and willing to provide a written informed consent.
Exclusion Criteria4
- Patients who cannot eat orally and have gastric emptying disorder after surgery;
- Patients with moderate diarrhea: diarrhea ≥4 times per day; the moderate and severe effluents from stoma increased; Or diarrhea that limits activities of daily living;
- Patients who cannot eat orally and have gastric emptying disorder after surgery;
- Patients who cannot eat orally and have gastric emptying disorder after surgery;
Interventions
DRUGIrinotecan liposome injection
Postoperative adjuvant therapy
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06361316
Related Trials
A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs
NCT056635158 locations
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
NCT046786483 locations
Resilience and Equity in Aging, Cancer, and Health (REACH)
NCT046742671 location
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
NCT0624477126 locations
ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors
NCT0697316127 locations